Indicator type;Main activity, secondary activity or tool required for...;Total
Companies carrying out R&D in Biotechnology;Total;1,602
Companies carrying out R&D in Biotechnology;Main;773
Companies carrying out R&D in Biotechnology;Secondary;279
Companies carrying out R&D in Biotechnology;Tool required;550
% Companies by type of biotechnology used: Genetic Code;Total;28.8
% Companies by type of biotechnology used: Genetic Code;Main;35.7
% Companies by type of biotechnology used: Genetic Code;Secondary;27.0
% Companies by type of biotechnology used: Genetic Code;Tool required;20.0
% Companies by type of biotechnology used: Functional Units;Total;38.9
% Companies by type of biotechnology used: Functional Units;Main;45.8
% Companies by type of biotechnology used: Functional Units;Secondary;37.8
% Companies by type of biotechnology used: Functional Units;Tool required;29.8
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering;Total;21.5
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering;Main;25.9
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering;Secondary;19.7
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering;Tool required;16.2
% Companies by type of biotechnology used: Bioprocesses;Total;49.5
% Companies by type of biotechnology used: Bioprocesses;Main;40.1
% Companies by type of biotechnology used: Bioprocesses;Secondary;56.6
% Companies by type of biotechnology used: Bioprocesses;Tool required;59.2
% Companies by type of biotechnology used: Subcellular Organisms;Total;8.7
% Companies by type of biotechnology used: Subcellular Organisms;Main;11.1
% Companies by type of biotechnology used: Subcellular Organisms;Secondary;6.4
% Companies by type of biotechnology used: Subcellular Organisms;Tool required;6.5
% Companies by type of biotechnology used: Bioinformatics;Total;26.9
% Companies by type of biotechnology used: Bioinformatics;Main;34.9
% Companies by type of biotechnology used: Bioinformatics;Secondary;23.5
% Companies by type of biotechnology used: Bioinformatics;Tool required;17.2
% Companies by type of biotechnology used: Nanobiotechnology;Total;11.8
% Companies by type of biotechnology used: Nanobiotechnology;Main;16.8
% Companies by type of biotechnology used: Nanobiotechnology;Secondary;9.7
% Companies by type of biotechnology used: Nanobiotechnology;Tool required;5.9
% Companies by type of biotechnology used: Other;Total;18.0
% Companies by type of biotechnology used: Other;Main;17.4
% Companies by type of biotechnology used: Other;Secondary;18.4
% Companies by type of biotechnology used: Other;Tool required;18.6
% Companies by final application areas of biotechnology use: Human Health;Total;48.4
% Companies by final application areas of biotechnology use: Human Health;Main;66.4
% Companies by final application areas of biotechnology use: Human Health;Secondary;37.1
% Companies by final application areas of biotechnology use: Human Health;Tool required;28.7
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture;Total;19.1
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture;Main;20.9
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture;Secondary;18.8
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture;Tool required;16.8
% Companies by final application areas of biotechnology use: Food Products;Total;28.9
% Companies by final application areas of biotechnology use: Food Products;Main;20.2
% Companies by final application areas of biotechnology use: Food Products;Secondary;32.9
% Companies by final application areas of biotechnology use: Food Products;Tool required;39.1
% Companies by final application areas of biotechnology use: Agriculture and Forestry;Total;24.8
% Companies by final application areas of biotechnology use: Agriculture and Forestry;Main;19.1
% Companies by final application areas of biotechnology use: Agriculture and Forestry;Secondary;30.4
% Companies by final application areas of biotechnology use: Agriculture and Forestry;Tool required;30.1
% Companies by final application areas of biotechnology use: Environment;Total;18.2
% Companies by final application areas of biotechnology use: Environment;Main;14.8
% Companies by final application areas of biotechnology use: Environment;Secondary;29.5
% Companies by final application areas of biotechnology use: Environment;Tool required;17.3
% Companies by final application areas of biotechnology use: Industry;Total;13.5
% Companies by final application areas of biotechnology use: Industry;Main;12.7
% Companies by final application areas of biotechnology use: Industry;Secondary;17.1
% Companies by final application areas of biotechnology use: Industry;Tool required;12.7
R&D personnel in Biotechnology (PP);Total;19,307
R&D personnel in Biotechnology (PP);Main;9,595
R&D personnel in Biotechnology (PP);Secondary;3,420
R&D personnel in Biotechnology (PP);Tool required;6,293
R&D personnel in Biotechnology (PP): Research personnel;Total;10,779
R&D personnel in Biotechnology (PP): Research personnel;Main;5,672
R&D personnel in Biotechnology (PP): Research personnel;Secondary;1,945
R&D personnel in Biotechnology (PP): Research personnel;Tool required;3,162
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;Total;8,528
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;Main;3,923
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;Secondary;1,474
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;Tool required;3,130
R&D personnel in Biotechnology (PP). Women;Total;11,155
R&D personnel in Biotechnology (PP). Women;Main;5,882
R&D personnel in Biotechnology (PP). Women;Secondary;1,909
R&D personnel in Biotechnology (PP). Women;Tool required;3,364
R&D personnel in Biotechnology (PP). Women: Research personnel;Total;5,934
R&D personnel in Biotechnology (PP). Women: Research personnel;Main;3,223
R&D personnel in Biotechnology (PP). Women: Research personnel;Secondary;1,036
R&D personnel in Biotechnology (PP). Women: Research personnel;Tool required;1,675
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;Total;5,222
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;Main;2,660
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;Secondary;873
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;Tool required;1,689
R&D personnel in Biotechnology (FTE);Total;14,093.7
R&D personnel in Biotechnology (FTE);Main;7,496.3
R&D personnel in Biotechnology (FTE);Secondary;2,228.2
R&D personnel in Biotechnology (FTE);Tool required;4,369.2
R&D personnel in Biotechnology (FTE): Research personnel;Total;8,073.8
R&D personnel in Biotechnology (FTE): Research personnel;Main;4,470.2
R&D personnel in Biotechnology (FTE): Research personnel;Secondary;1,271.2
R&D personnel in Biotechnology (FTE): Research personnel;Tool required;2,332.4
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;Total;6,019.9
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;Main;3,026.1
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;Secondary;957.0
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;Tool required;2,036.8
R&D personnel in Biotechnology (FTE). Women;Total;8,305.8
R&D personnel in Biotechnology (FTE). Women;Main;4,623.1
R&D personnel in Biotechnology (FTE). Women;Secondary;1,273.3
R&D personnel in Biotechnology (FTE). Women;Tool required;2,409.5
R&D personnel in Biotechnology (FTE). Women: Research personnel;Total;4,482.6
R&D personnel in Biotechnology (FTE). Women: Research personnel;Main;2,545.4
R&D personnel in Biotechnology (FTE). Women: Research personnel;Secondary;684.2
R&D personnel in Biotechnology (FTE). Women: Research personnel;Tool required;1,253.0
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;Total;3,823.2
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;Main;2,077.7
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;Secondary;589.1
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;Tool required;1,156.5
Expenditure on internal R&D in Biotechnology (thousands of euros);Total;1,462,695
Expenditure on internal R&D in Biotechnology (thousands of euros);Main;791,776
Expenditure on internal R&D in Biotechnology (thousands of euros);Secondary;281,859
Expenditure on internal R&D in Biotechnology (thousands of euros);Tool required;389,060
1) By type of expenditure: Current expenditure;Total;1,347,574
1) By type of expenditure: Current expenditure;Main;722,397
1) By type of expenditure: Current expenditure;Secondary;267,005
1) By type of expenditure: Current expenditure;Tool required;358,172
1.1) Labour expenditure of research personnel;Total;470,714
1.1) Labour expenditure of research personnel;Main;258,146
1.1) Labour expenditure of research personnel;Secondary;87,519
1.1) Labour expenditure of research personnel;Tool required;125,049
1.2) Labour expenditure of technical and auxiliary personnel;Total;258,791
1.2) Labour expenditure of technical and auxiliary personnel;Main;128,142
1.2) Labour expenditure of technical and auxiliary personnel;Secondary;39,887
1.2) Labour expenditure of technical and auxiliary personnel;Tool required;90,762
1.3) Other current expenditure;Total;618,069
1.3) Other current expenditure;Main;336,109
1.3) Other current expenditure;Secondary;139,599
1.3) Other current expenditure;Tool required;142,361
2) By type of expenditure: Capital expenditure;Total;115,121
2) By type of expenditure: Capital expenditure;Main;69,379
2) By type of expenditure: Capital expenditure;Secondary;14,854
2) By type of expenditure: Capital expenditure;Tool required;30,888
2.1) Land and buildings;Total;21,877
2.1) Land and buildings;Main;12,452
2.1) Land and buildings;Secondary;1,281
2.1) Land and buildings;Tool required;8,144
2.2) Equipment and tools;Total;54,592
2.2) Equipment and tools;Main;26,091
2.2) Equipment and tools;Secondary;10,937
2.2) Equipment and tools;Tool required;17,563
2.3) Acquisition of specific R&D software;Total;4,673
2.3) Acquisition of specific R&D software;Main;2,604
2.3) Acquisition of specific R&D software;Secondary;803
2.3) Acquisition of specific R&D software;Tool required;1,266
2.4) Other R&D-specific IP products;Total;33,978
2.4) Other R&D-specific IP products;Main;28,231
2.4) Other R&D-specific IP products;Secondary;1,833
2.4) Other R&D-specific IP products;Tool required;3,914
1.1) By origin of funds: Own funds;Total;1,013,505
1.1) By origin of funds: Own funds;Main;506,869
1.1) By origin of funds: Own funds;Secondary;212,196
1.1) By origin of funds: Own funds;Tool required;294,440
1.2) By origin of funds: Funds from the Business sector;Total;206,072
1.2) By origin of funds: Funds from the Business sector;Main;133,006
1.2) By origin of funds: Funds from the Business sector;Secondary;31,303
1.2) By origin of funds: Funds from the Business sector;Tool required;41,763
1.3) By origin of funds: Funds from the Public Administration sector;Total;158,706
1.3) By origin of funds: Funds from the Public Administration sector;Main;94,278
1.3) By origin of funds: Funds from the Public Administration sector;Secondary;28,526
1.3) By origin of funds: Funds from the Public Administration sector;Tool required;35,902
1.4) By origin of funds: Funds from the Higher Education sector;Total;615
1.4) By origin of funds: Funds from the Higher Education sector;Main;514
1.4) By origin of funds: Funds from the Higher Education sector;Secondary;0
1.4) By origin of funds: Funds from the Higher Education sector;Tool required;101
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;Total;9,828
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;Main;8,757
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;Secondary;38
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;Tool required;1,033
1.6) By origin of funds: Funds from the rest of the world;Total;73,969
1.6) By origin of funds: Funds from the rest of the world;Main;48,351
1.6) By origin of funds: Funds from the rest of the world;Secondary;9,796
1.6) By origin of funds: Funds from the rest of the world;Tool required;15,821
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);Total;96,238
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);Main;75,967
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);Secondary;12,035
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);Tool required;8,236
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;Total;65,364
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;Main;50,684
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;Secondary;7,546
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;Tool required;7,134
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;Total;30,874
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;Main;25,283
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;Secondary;4,489
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;Tool required;1,102
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital;Total;46.1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital;Main;54.5
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital;Secondary;43.9
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital;Tool required;35.4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;Total;17.1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;Main;14.9
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;Secondary;19.8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;Tool required;18.9
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;Total;25.9
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;Main;25.7
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;Secondary;24.4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;Tool required;26.9
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;Total;13.4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;Main;12.2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;Secondary;14.3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;Tool required;14.7
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;Total;18.6
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;Main;21.8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;Secondary;18.2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;Tool required;14.2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;Total;17.3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;Main;20.4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;Secondary;15.2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;Tool required;13.9
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;Total;20.1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;Main;21.1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;Secondary;18.4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;Tool required;19.4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;Total;47.4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;Main;54.7
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;Secondary;43.8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;Tool required;38.9
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost;Total;53.7
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost;Main;59.5
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost;Secondary;51.8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost;Tool required;46.4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;Total;21.6
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;Main;20.4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;Secondary;27.4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;Tool required;20.6
% Companies with international revenues related to biotechnology activities;Total;22.2
% Companies with international revenues related to biotechnology activities;Main;29.6
% Companies with international revenues related to biotechnology activities;Secondary;16.8
% Companies with international revenues related to biotechnology activities;Tool required;14.5
% Companies representing international revenues related to biotechnology activities;Total;2.2
% Companies representing international revenues related to biotechnology activities;Main;16.8
% Companies representing international revenues related to biotechnology activities;Secondary;0.6
% Companies representing international revenues related to biotechnology activities;Tool required;1.6
% International revenues related to biotechnology activities distributed in: Revenues from the EU;Total;55.2
% International revenues related to biotechnology activities distributed in: Revenues from the EU;Main;66.4
% International revenues related to biotechnology activities distributed in: Revenues from the EU;Secondary;34.1
% International revenues related to biotechnology activities distributed in: Revenues from the EU;Tool required;43.4
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world;Total;44.8
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world;Main;33.6
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world;Secondary;65.9
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world;Tool required;56.6
% International revenues related to biotechnology activities by classification: International trade in goods and services;Total;87.2
% International revenues related to biotechnology activities by classification: International trade in goods and services;Main;80.7
% International revenues related to biotechnology activities by classification: International trade in goods and services;Secondary;97.2
% International revenues related to biotechnology activities by classification: International trade in goods and services;Tool required;95.0
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Total;4.6
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Main;7.1
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Secondary;0.3
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Tool required;1.8
% International revenues related to biotechnology activities by classification: Subsidies from external sources;Total;4.3
% International revenues related to biotechnology activities by classification: Subsidies from external sources;Main;6.6
% International revenues related to biotechnology activities by classification: Subsidies from external sources;Secondary;2.6
% International revenues related to biotechnology activities by classification: Subsidies from external sources;Tool required;0.7
% International revenues related to biotechnology activities by classification: Other;Total;3.9
% International revenues related to biotechnology activities by classification: Other;Main;5.6
% International revenues related to biotechnology activities by classification: Other;Secondary;0.0
% International revenues related to biotechnology activities by classification: Other;Tool required;2.4